罗氏控股
RHHBY
57.14
+0.36
+0.63%
罗氏控股
US · RHHBY
#49 按市值排名
上市于 1970
57.14
+0.36
+0.63%
实时 - 追踪5344个代码 - 心跳于385秒前
· 2026-10-17 16:10
最新新闻
-
Morgan Stanley Upgrades ROCHE HOLDING AG(RHHBY.US) to Buy Rating, Raises Target Price to $507.41\u5e02\u573a\u8d44\u8baf · 2026/8/7
-
评级变动
TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $67\u5e02\u573a\u8d44\u8baf · 2026/2/11
-
评级变动
HSBC Maintains ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Raises Target Price to $57\u5e02\u573a\u8d44\u8baf · 2025/12/10
-
评级变动
HSBC Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $50\u5e02\u573a\u8d44\u8baf · 2025/10/2
-
评级变动
The latest pharmaceutical industry rating by S&P reveals that Johnson & Johnson (JNJ.US) and Roche (RHHBY.US) are ranked at the top for superior financial and innovative abilities.Zhitong Finance · 2024/8/19
-
评级变动
Argus Research Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating, Announces Target Price $55\u5e02\u573a\u8d44\u8baf · 2026/4/6
-
评级变动
TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Maintains Target Price $43\u5e02\u573a\u8d44\u8baf · 2025/7/24
-
评级变动
Goldman Sachs Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating\u5e02\u573a\u8d44\u8baf · 2026/1/16
-
The Center for Drug Evaluation (CDE) has accepted Roche's (RHHBY.US) marketing application for faricimab injection, indicated for the treatment of uveitic macular edema.Zhitong Finance · 2026/9/4
-
Roche (RHHBY.US) submits BTK inhibitor for market approvalZhitong Finance · 2026/9/30
-
评级变动
Morgan Stanley Initiates ROCHE HOLDING AG(RHHBY.US) With Sell Rating, Announces Target Price $46\u5e02\u573a\u8d44\u8baf · 2026/4/7
-
评级变动
Analysts Offer Insights on Healthcare Companies: SCHOTT Pharma AG & Co. KGaA (1SXP) and Roche Holding (RHHBY)TipRanks · 2025/12/6
-
评级变动
TD Cowen Maintains ROCHE HOLDING AG(RHHBY.US) With Hold Rating, Raises Target Price to $67\u5e02\u573a\u8d44\u8baf · 2026/2/10
-
Roche (RHHBY.US) reports positive mid-stage trial results for its weight-loss injection: average weight reduction of 15.5% over 48 weeks, with a 2.65% decrease in blood glucose indicators.Zhitong Finance · 2026/9/22
-
评级变动
Barclays Initiates ROCHE HOLDING AG(RHHBY.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/1/7
-
评级变动
Erste Group Initiates ROCHE HOLDING AG(RHHBY.US) With Hold Rating\u5e02\u573a\u8d44\u8baf · 2024/11/5
-
From treatment to prevention! Roche (RHHBY.US) initiates clinical trial of Brainshuttle therapy for Alzheimer's diseaseZhitong Finance · 2026/7/15
新闻标题为自动聚合内容,未经我们团队独立核实或编辑。
报价时间 2026-10-17 16:10:31 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
diagnostics arm doesn’t get enough credit next to the pharma pipeline headlines. currency moves swing the adr price more than the underlying business most quarters.